BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35243746)

  • 21. The H
    Lignelli E; Palumbo F; Bayindir SG; Nagahara N; Vadász I; Herold S; Seeger W; Morty RE
    Nitric Oxide; 2021 Feb; 107():31-45. PubMed ID: 33338600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
    Liu T; Chen J; Xiao S; Lei X
    Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4.
    Zhou W; Zou B; Liu L; Cui K; Gao J; Yuan S; Cong N
    Oncotarget; 2016 Nov; 7(45):74059-74073. PubMed ID: 27677076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting α-SMA.
    Pan Y; Qin T; Yin S; Zhang X; Gao X; Mu L
    Biomed Pharmacother; 2017 Mar; 87():669-677. PubMed ID: 28088733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
    Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
    J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR‑300 regulates tumor proliferation and metastasis by targeting lymphoid enhancer‑binding factor 1 in hepatocellular carcinoma.
    Chen Y; Guo Y; Li Y; Yang J; Liu J; Wu Q; Wang R
    Int J Oncol; 2019 Apr; 54(4):1282-1294. PubMed ID: 30968150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
    Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
    BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 31. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
    Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
    Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
    Yao Y; Dou C; Lu Z; Zheng X; Liu Q
    Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4.
    Yang X; Sun L; Wang L; Yao B; Mo H; Yang W
    Biomed Pharmacother; 2019 Oct; 118():109386. PubMed ID: 31545291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
    Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
    J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
    Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
    Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.
    Zhao JJ; Pan K; Li JJ; Chen YB; Chen JG; Lv L; Wang DD; Pan QZ; Chen MS; Xia JC
    PLoS One; 2011; 6(10):e26608. PubMed ID: 22028922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway.
    Zhang JG; Shi Y; Hong DF; Song M; Huang D; Wang CY; Zhao G
    Sci Rep; 2015 Jan; 5():8087. PubMed ID: 25627001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
    Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
    World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.